SCHEMBL6294909

SCHEMBL6294909

CCOc1ccc(C(=O)O)cc1S(C)(=O)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.60
POLB P06746 1/20 0.52
CASP6 P55212 1/20 0.52
THRA P10827 1/20 0.52
THRB P10828 1/20 0.52
PKM P14618 1/20 0.51
TTR P02766 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.47
LMNA P02545 1/20 0.47
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
USP2 O75604 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CREBBP Q92793 4/20 0.46
MAPT P10636 1/20 0.46
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9018714 0.86 PKM (0.50) TSHRPOLBCASP6THRATHRB
SCHEMBL27341276 0.82 RXRA (0.52) MRGPRX4
SCHEMBL2565798 0.82 PKM (0.73) TSHRPOLBPKMTTRNPSR1
SCHEMBL29882038 0.80 TSHR (0.83) TSHRPOLBCASP6THRBNPSR1
SCHEMBL177424 0.80 TSHR (0.83) TSHRPOLBCASP6THRBNPSR1
SCHEMBL28389116 0.78 RAB9A (0.60) POLBPKMMRGPRX4NPC1RAB9A
SCHEMBL8073502 0.78 TTR (0.51) POLBPKMTTRNPSR1MAPT
SCHEMBL2562181 0.78 NPSR1 (0.54) TSHRPOLBTHRATHRBPKM
SCHEMBL15662236 0.78 TSHR (0.56) TSHRPOLBCASP6SMN1; SMN2HSD17B10
SCHEMBL9018673 0.77 PKM (0.50) TSHRPOLBTHRATHRBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6841560-B2 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. (GB) 2005-01-11 US disclosed
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2004-10-21 US disclosed
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders SMITHKLINE BEECHAM P.L.C. 2003-07-31 US disclosed
EP-0968190-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-01-05 EP disclosed
WO-1998041508-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1998-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209912-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A TSHR 4289/4885POLB 3366/4885CASP6 1557/4885
US-20030144320-A1 For treatment and/or prevention of anxiety, mania, depression, panic disorders, nerve sustem disorders PNMT, SLC6A2, GABBR1 TSHR 942/4885POLB 2764/4885CASP6 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.